NURS 6630 summer 2025 Psychopharmacology Final Exam Graded Review Test Submission Week 11 Final ExAM.pdf

1


NURS 6630 summer 2025
Psychopharmacology Final Exam Graded
Review Test Submission Week 11Final
ExAM
Question 1 1 out of 1 points
An adult patient presents with a history of substance-use disorder and attention
deficit hyperactivitydisorder (ADHD). Which ofthefollowingtreatment options is
bestforthispatient?

Selected Answer: b. Atomoxetine

Question 2 1 out of 1 points
The PMHNP understands that varenicline (CHANTIX) is an effective way to assist patients
with
smoking cessation. Why is this medication effective for these patients?

Selected c.
Answer: Varenicline is a selective nicotinic acetylcholine receptor partial
agonist


Question 3 1 out of 1 points
Which patient will receive a lower dose of
guanfacine?

Selected Answer: d.Patient with kidney disease 1 out of 1 points

Question 4




pg. 1

,2


The PMHNP is attempting to treat a patient’s chronic pain by having the agent bind the
open channelconformation of VSCCstoblock thosechannelswitha“use-dependent”
formof inhibition. Which agent will the PMHNP most likely select?

Selected Answer: b. Pregabalin (Lyrica)


Question 5 1 out of 1 points
Which of the following substances has the highest probability of becoming dependent
after a single use?

Selected Answer: a. Nicotine


Question 6 1 out of 1 points

A PMHNP supervisor is discussing with a nursing student how stimulants and
noradrenergic agents assist with ADHD symptoms. What is the appropriate
response?
Selected Answer: d. All of these are correct


Question 7 1 out of 1 points
All drugs that lead to addiction increase in the ventral striatum, which is
also called the .

Selected Answer: a. Dopamine / nucleus accumbens


Question 8 1 out of 1 points
The PMHNP is teaching a patient with a sleep disorder about taking
diphenhydramine (Benadryl). The patient is concerned about the side e"ects of the
drug. What can the PMHNP teach the patient about this treatment approach?

Selected Answer: a. “It can cause blurred vision.”


Question 9 1 out of 1 points
The PMHNP is assessing afemale patientwhohasbeentakinglamotrigine
(Lamictal) for migraine prophylaxis. After discovering that the patient has reached the
maximum dose of this medication, the PMHNP decides to change the patient’s
pg. 2

, 3
medication to zonisamide (Zonegran). In addition to evaluating this patient’s day-to-day
activities, what should the PMHNP ensure that this patient understands?
SelectedAnswer:
d.
This medication has unwanted side e"ects such as sedation, lack of coordination, and drowsiness.


Question 10 1 out of 1 points
Daniel is a 33 year old patient with ADHD and multiple comorbidities: mood disorder,
alcohol abuse, ADHD, and nicotine dependence. Which comorbidity should be
treated first?

Selected Answer: a. Alcohol abuse disorder


Question 11 1 out of 1 points
Individuals who su"er from an addiction often increase the dose of medication to
achieve the desired e"ect. The need to increase the dose to reach the safe e"ect is due to .

Selected Answer: d. tolerance


Question 12 1 out of 1 points
Sharon is a 56-year-old female that presents to the clinic with pain after su"ering a back
injury several years ago. The patient states she feels a tingling sensation in her legs. What
type of pain is Sharon likely experiencing?

Selected Answer: b. Neuropathic pain


Question 13 1 out of 1 points
The PMHNP is evaluating a 7 year old pediatric patient for the treatment of ADHD.
The PMHNP decidestoprescribeamedicationthatisselectiveforalpha-
2Areceptorsthathasalower incidence of sedation and hypotension. Which agent
did the PMHNP prescribe?
Selected Answer: b. Guanfacine (INTUNIV)


Question 14 1 out of 1 points
Mr. Peterson is meeting with the PMHNP to discuss healthier dietary habits. With a
pg. 3